Association of LOX expression with the survival of breast cancer patients.

<p>Kaplan-Meier analyses of the overall (A, D), disease-free (B, E, H) and metastasis-free survival (C, F, I) in unse­lected patients (A–C; n = 105) and in ER-negative patients (D–F; n = 58) are shown. (G) Strip-chart of individual patients with their corresponding ER-status and relative LOX expression levels. Patients were stratified into four groups according to those two parameters: LOX high/ER−, LOX low/ER−, LOX high/ER+, and LOX low/ER+. (H, I) Kaplan-Meier analyses of the four groups established in (G). LOX high, relative LOX expression >1.094; LOX low, relative LOX expression <1.094; ER−, estrogen receptor negative; ER+, estrogen receptor positive.